Bisphosphonate class drugs

6 results
A-S Medication Solutions
Usage: Alendronate sodium tablets are indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and managing Paget's disease of bone. Periodic reevaluation of therapy necessity is recommended.
Sun Pharmaceutical Industries, Inc.
Usage: Ibandronate sodium injection is indicated for treating osteoporosis in postmenopausal women, as it increases bone mineral density and reduces vertebral fracture incidence. Long-term safety and effectiveness have not been established, and the need for continued therapy should be re-evaluated periodically.
Macleods Pharmaceuticals Limited
Usage: Ibandronate sodium tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women, increasing bone mineral density and reducing vertebral fractures. Long-term safety and effectiveness are not fully established; patients should periodically reassess the need for continued therapy, especially after 3-5 years.
Apotex Corp.
Usage: Ibandronate sodium injection is indicated for treating osteoporosis in postmenopausal women, as it increases bone mineral density and lowers vertebral fracture incidence. Its long-term safety and effectiveness are based on one year of clinical data, necessitating periodic reevaluation of the need for continued therapy.
Aurobindo Pharma Limited
Usage: Ibandronate sodium tablets are indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mineral density and reducing vertebral fractures. Long-term safety and efficacy are not fully established; ongoing evaluation of treatment necessity is recommended, particularly for patients at low fracture risk after 3 to 5 years.
Accord Healthcare Inc.
Usage: Ibandronate Sodium Injection is indicated for treating osteoporosis in postmenopausal women, increasing bone mineral density and reducing vertebral fracture incidence. Treatment duration is based on one year of clinical data, requiring periodic re-evaluation of therapy necessity, particularly for those at low fracture risk after 3 to 5 years.